Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 April 2020 | Story Department of Communication and Marketing | Photo Charl Devenish
Farmovs
In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.

The University of the Free State (UFS) is committed to supporting government’s efforts to overcome the COVID-19 pandemic. During this challenging time, dedicated staff members at the UFS continue to provide services as a testimony to their commitment to advance public knowledge of COVID-19 for the greater good of South Africa.

The following is a synopsis of the areas in which the UFS is actively assisting.

Public Health Emergency Solidarity Trial
Clinicians from the Department of Internal Medicine, the Department of Critical Care, and the Division of Virology will be working with FARMOVS to participate in the Public Health Emergency Solidarity Trial initiated by the World Health Organization (WHO). This international randomised trial will evaluate four treatment options (remdesivir, lopinavir/ritonavir, lopinavir/ritonavir plus interferon, chloroquine or hydroxychloroquine) for the treatment of COVID-19. 

The trial is expected to include more than 45 countries worldwide, including a number of South African sites. 

Farmovs

FARMOVS is in a planning process to support all the Bloemfontein hospitals, including Pelonomi, Universitas, 3 Military Hospital, Mediclinic, and Rosepark, in conducting the largest global trial on COVID-19 – the Public Health Emergency Solidarity Trial, under leadership of the WHO.   

Negotiations are ongoing between the UFS and the Department of Health in the Free State for FARMOVS to offer support with the continuation of healthcare to non-COVID-19 patients in an attempt to free up space at Universitas Hospital for isolation of COVID-19 patients. 

In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.  FARMOVS also receives feasibility requests for support with the evaluation of existing drugs (repurposing) as well as the development of novel drugs for the treatment of COVID-19 – this is an ongoing process.

Disaster Management Training and Education Centre (DiMTEC)
DiMTEC represents the UFS on the Provincial Joint Operation Centre (PROVJOC). The PROVJOC is a fully equipped, dedicated facility that is proactively established to enable all relevant role players /disciplines to jointly manage all safety and security-related aspects of any planned event or any major incident which has occurred or is imminent – especially in the response and recovery operations phase – at the strategic and/or tactical level, using the Unified Command System. This facility is also linked to all other established safety and security centres.

Research and Innovation
The UFS hosts a SARChI Research Chair in vector-borne and zoonotic diseases, and recently invested in the establishment of a biosafety level-3 facility. Hence, there is expertise on the campus to plan and conduct research on zoonotic and medically significant viruses. In addition, there are research groups focusing on protein expression systems with potential for utilisation in the development of diagnostic assays with application in either diagnosis or surveillance.

Currently, researchers at the UFS have established several projects that will contribute directly towards the COVID-19 outbreak.


News Archive

Prof Tredoux turns theories regarding the formation of metals on its head
2013-09-17

 

Prof Marian Tredoux
17 September 2013

The latest research conducted by Prof Marian Tredoux of the Department of Geology, in collaboration with her research assistant Bianca Kennedy and their colleagues in Germany, placed established theories regarding how minerals of the platinum-group of elements are formed, under close scrutiny.

The article on this research of which Prof Tredoux is a co-author – ‘Noble metal nanoclusters and nanoparticles precede mineral formation in magmatic sulphide melts’ – was published in Nature Communications on 6 September 2013. It is an online journal for research of the highest quality in the fields of biological, physical and chemical sciences.

This study found that atoms of platinum and arsenic create nanoclusters, long before the mineral sperrylite can crystallise. Thus, the platinum does not occur as a primary sulphur compound. The research was conducted at the Steinmann Institute of the University of Bonn, Germany, as well as here in Bloemfontein.

Monetary support from Inkaba yeAfrica – a German-South African multidisciplinary and intercultural Earth Science collaborative of the National Research Foundation (NRF) – made this research possible. Studies are now also being conducted on other metals in the precious metal group, specifically palladium, rhodium and ruthenium.

The discovery of the nanoclusters and the combination with arsenic can have far-reaching consequences for the platinum mine industry, if it can be utilised to recover a greater amount of platinum ore and therefore less wastage ending up in mine dumps. This will signify optimal mining of a scarce and valuable metal, one of South Africa’s most important export products.

For Prof Tredoux, the research results also prove thoughts she already had some twenty years ago around the forming of platinum minerals. “Researchers laughed in my face, but the evidence had to wait for the development of technology to prove it.” Young researchers were very excited at recent congresses about the findings, since the new models can bring new insights.

“Chemistry researchers have been talking about platinum element clusters in watery environments for quite a while, but it was thought that these would not appear in magmas (molten rock) due to the high temperatures (>1 000 degrees celsius).”

Prof Tredoux has already delivered lectures at congresses in Scotland, Hungary, Sweden and Italy on this research.

Read the article at: http://www.nature.com/ncomms/2013/130906/ncomms3405/full/ncomms3405.html

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept